Note 31: Relationships with Third-Parties
Remuneration of key management
Key management consists of the members of the Executive Management Team and the entities controlled by any of them.
| As of December 31, |
||||||||||||
| 2017 | 2016 | 2015 | ||||||||||
|
Number of EMT members |
8 | 8 | 6 | |||||||||
|
(€‘000) |
For the years ended December 31, | |||||||||||
| 2017 | 2016 | 2015 | ||||||||||
|
Short term employee benefits[1] |
666 | 816 | 309 | |||||||||
|
Post employee benefits |
14 | 35 | 6 | |||||||||
|
Share-based compensation |
1,123 | 1,790 | 561 | |||||||||
|
Other employment costs[2] |
30 | 22 | 4 | |||||||||
|
Management fees |
1,950 | 2,055 | 1,299 | |||||||||
|
|
|
|
|
|
|
|||||||
|
Total benefits |
3,783 | 4,718 | 2,179 | |||||||||
|
|
|
|
|
|
|
|||||||
| [1] | Includes salaries, social security, bonuses, and lunch vouchers |
| [2] | Such as Company cars |
| 1 | Paid as of December 31, 2016 |
| As of December 31, | ||||||||||||
| 2017 | 2016 | 2015 | ||||||||||
|
Number of warrants granted |
179,000 | 180,000 | 5,000 | |||||||||
|
Number of warrants lapsed |
(15,225 | ) | (56,500 | ) | 10,000 | |||||||
|
Cumulative outstanding warrants |
306,500 | 310,725 | 187,225 | |||||||||
|
Exercised warrants |
168,000 | — | — | |||||||||
|
Outstanding payables (in ‘000€) |
461 | 687 | 537 | |||||||||
|
|
|
|
|
|
|
|||||||
Transactions with non-executive directors
|
For the year ended December 31, |
||||||||||||
|
(€‘000) |
2017 | 2016 | 2015 | |||||||||
|
Share-based compensation |
485 | 697 | 51 | |||||||||
|
Management fees |
387 | 363 | 89 | |||||||||
|
|
|
|
|
|
|
|||||||
|
Total benefits |
872 | 1,060 | 140 | |||||||||
|
|
|
|
|
|
|
|||||||
| As of December 31, | ||||||||||||
| 2017 | 2016 | 2015 | ||||||||||
|
Number of warrants granted |
60,000 | 50,000 | — | |||||||||
|
Number of warrants lapsed |
(2,904 | ) | — | — | ||||||||
|
Number of exercised warrants |
— | — | 5,000 | |||||||||
|
Cumulative outstanding warrants |
115,000 | 57,904 | 7,904 | |||||||||
|
Outstanding payables (in ‘000€) |
194 | 148 | 80 | |||||||||
|
Shares owned |
2,512,004 | 2,869,685 | 3,443,065 | |||||||||
|
|
|
|
|
|
|
|||||||
Transactions with shareholders
| For the years ended December 31, | ||||||||||||
|
(€‘000) |
2017 | 2016 | 2015 | |||||||||
|
Rent(1) |
— | 99 | 299 | |||||||||
|
Patent costs(2) |
— | — | 93 | |||||||||
|
Other |
— | — | — | |||||||||
|
|
|
|
|
|
|
|||||||
|
Total |
— | 99 | 392 | |||||||||
|
|
|
|
|
|
|
|||||||
| [1] | Relate to lease paid to Biological Manufacturing Services, company controlled by Tolefi SA until April 30, 2016 |
| [2] | Relate to Mayo License depreciation |
| [3] | Relate to directed research grant paid to Mayo Clinic under License Agreement |
| As of December 31, | ||||||||||||
|
(€‘000) |
2017 | 2016 | 2015 | |||||||||
|
Outstanding payables |
— | — | 39 | |||||||||
|
|
|
|
|
|
|
|||||||